GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales Conference call today […]
Written by NCV Newswire.
View the original article at here.
Publicly Traded Cannabis Stock News – New Cannabis Ventures
www.newcannabisventures.com
